|
Education:
| |
 |
June
1983 University of Massachusetts, School of Medicine |
| |
|
Worcester,
Massachusetts |
| |
|
May
1979 Dartmouth College |
| |
|
Bachelor
of Science, Biochemistry Cum Laude |
Postgraduate
Training:
| |
|
1984-1989
University of Pittsburgh Medical School Eye and
Ear Hospital Residency in Ophthalmology Pittsburgh,
PA |
| |
|
1983-1984
University of Massachusetts Medical Center Internship
in Internal Medicine Worcester, MA |
Experience:
| |
|
1987-1989
Eye Surgeons Associates Davenport, Iowa |
| |
|
1989-1996
Florida Eye Care Melbourne, FL |
Hospital
Affiliations:
| |
|
Holmes
Regional Medical Center Melbourne, FL |
| |
|
Wuesthoff
Hospital Rockledge, FL |
| |
|
HealthSouth
Surgery Center Melbourne, FL
|
Specialty
Certification/Membership in Professional Societies:
| |
|
Board
Certified, American Board of Ophthalmology |
| |
|
American
Academy of Ophthalmology |
| |
|
American
Medical Association |
| |
|
Florida
Medical Association |
| |
|
Florida
Society of Ophthalmology |
| |
|
Brevard
County Medical Society |
Research
Experience:
| |
|
Use
of Apraclonidine for Compassionate Adjunctive
Medical Therapy in Patients with Poorly Controlled
Intraocular Pressure Protocol C-859-66 (1) Alcon
Laboratories, Inc. |
| |
|
Clinical
Trial for an Advanced Computerized Macular Degeneration
Test and Comparison with Amsler Grid Florida Institute
of Technology 1992-1995 |
| |
|
Tolerability
and Safety of 2% MK-0509 (Dorzolamide Hydrochloride)
for the Treatment of Elevated Intraocular Pressure
in Patients with Ocular Hypertension or Open Angle
Glaucoma 1995 |
| |
|
Evaluation
of the efficacy and pharmacoeconomics of Alphagan
compared to patient’s current two line therapy
to maintain intraocular pressure. ORA Protocol
98-62 Allergan 1998 |
| |
|
A
Multi-Center, Investigator-Masked, Randomized,
Parallel Study of the Safety and Efficacy of AGN
192924 0.03% Ophthalmic Solution Compared with
Latanoprost 0.005% Ophthalmic Solution Administered
Once-Daily in Subjects With Glaucoma or Ocular
Hypertension. Protocol 192024-010-00 Allergan
1999 |
| |
|
A
Multicenter, Double-Masked, Randomized, Parallel
Study of the Safety and Efficacy of 0.2% Brimonidine
Tartrate/ 0.5% Timolol Combination Ophthalmic
Solution Twice-Daily Compared with 0.5% Timolol
Twice-Daily or Alphagan Three-Times-Daily for
Three Months (plus 9-Month, Masked Extension)
in Patients with Glaucoma or Ocular Hypertension.
Protocol 190342-012T Allergan 2000 |
|
